B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2025

This B-Cell Maturation Antigen (BCMA) Targeted Therapies market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The B-cell maturation antigen (BCMA) targeted therapies market size has grown exponentially in recent years. It will grow from $12.17 billion in 2024 to $15.21 billion in 2025 at a compound annual growth rate (CAGR) of 25%. The growth during the historical period can be attributed to an increasing focus on hematologic malignancies, rising investments in oncology research, a growing demand for personalized medicine, higher adoption of CAR-T cell therapies, and rising healthcare expenditure.

The B-cell maturation antigen (BCMA) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $36.66 billion in 2029 at a compound annual growth rate (CAGR) of 24.6%. The expected growth in the forecast period is driven by a continued focus on cancer research, a shift toward targeting specific molecular markers, the rising incidence of cancers, a surge in biotech investments, and the expanding use of cell and gene therapies. Key trends in the forecast period include innovations such as CRISPR technology, advancements in gene-editing technologies, the development of next-generation CAR-T cell therapies, progress in targeted antibody-drug conjugates, and the creation of off-the-shelf treatments.

The growing prevalence of multiple myeloma is anticipated to drive the expansion of the B-cell maturation antigen (BCMA) targeted therapies market. Multiple myeloma, a cancer that mainly impacts plasma cells - vital components of the immune system responsible for antibody production - is becoming more common due to factors such as an aging global population, enhanced diagnostic tools, and varying levels of healthcare access. BCMA-targeted therapies are essential for treating this condition, as they focus on eliminating malignant plasma cells expressing BCMA, offering a more precise and effective treatment option. For example, the American Cancer Society projected that in 2024, the United States would see approximately 35,780 new multiple myeloma cases, including 19,520 in men and 16,260 in women. The expected death toll is around 12,540, with 7,020 male deaths and 5,520 female deaths. As a result, the increasing incidence of this cancer is fueling growth in the BCMA-targeted therapies market.

Leading companies in the B-cell maturation antigen (BCMA) targeted therapies market are focusing on developing cutting-edge treatments such as CAR-T cell therapy to improve the effectiveness and accuracy of targeting cancer cells. CAR-T cell therapy is an immunotherapy that involves altering a patient's T cells to express chimeric antigen receptors (CARs), enabling them to specifically attack and eliminate cancer cells. For example, in April 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically modified autologous T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma who have undergone at least one previous line of treatment and are resistant to lenalidomide.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for around $1.2 billion. This acquisition is aimed at strengthening AstraZeneca’s cell therapy portfolio by incorporating Gracell's FasTCAR-enabled GC012F therapy, which targets cancer and autoimmune diseases, addressing critical unmet medical needs. Gracell Biotechnologies, based in China, specializes in developing BCMA therapies for multiple myeloma and B-cell malignancies.

Major players in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, Beigene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Juno Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Teneobio Inc., Janssen Pharmaceuticals Companies, Allogene Therapeutics, Affimed, Bluebird Bio Inc.

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2024. The regions covered in B-cell maturation antigen (BCMA) targeted therapies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the B-cell maturation antigen (BCMA) targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

B-cell maturation antigen (BCMA) targeted therapies are a class of treatments designed to specifically target BCMA, a protein found on the surface of mature B-cells and plasma cells. BCMA, a member of the tumor necrosis factor (TNF) receptor superfamily, plays an essential role in B-cell development, survival, and differentiation into plasma cells. These therapies represent a significant advancement in treating multiple myeloma, providing effective options for patients with relapsed or refractory disease.

The main types of products in BCMA-targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. ADCs are targeted treatments that attach a cancer-specific antibody to a cytotoxic drug, allowing for the precise destruction of cancer cells while minimizing damage to healthy tissue. The primary indications for these therapies include acute lymphoblastic leukemia and multiple myeloma. These treatments are used by various end users, such as hospitals, specialty clinics, and home care settings.

The B-cell maturation antigen (BCMA) targeted therapies market research report is one of a series of new reports that provides B-cell maturation antigen (BCMA) targeted therapies market statistics, including the B-cell maturation antigen (BCMA) targeted therapies industry global market size, regional shares, competitors with the B-cell maturation antigen (BCMA) targeted therapies market share, detailed B-cell maturation antigen (BCMA) targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the B-cell maturation antigen (BCMA) targeted therapies industry. This B-cell maturation antigen (BCMA) targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.